Avery Dennison to Webcast Second Quarter 2025 Earnings Conference Call
The event will be webcast live, and the replay will be available on Avery Dennison's Investor Relations website (www.investors.averydennison.com).
About Avery Dennison
Avery Dennison Corporation (NYSE: AVY) is a global materials science and digital identification solutions company. We are Making Possible™ products and solutions that help advance the industries we serve, providing branding and information solutions that optimize labor and supply chain efficiency, reduce waste, advance sustainability, circularity and transparency, and better connect brands and consumers. We design and develop labeling and functional materials, radio-frequency identification (RFID) inlays and tags, software applications that connect the physical and digital, and offerings that enhance branded packaging and carry or display information that improves the customer experience. Serving industries worldwide — including home and personal care, apparel, general retail, e-commerce, logistics, food and grocery, pharmaceuticals and automotive — we employ approximately 35,000 employees in more than 50 countries. Our reported sales in 2024 were $8.8 billion. Learn more at www.averydennison.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
32 minutes ago
- Associated Press
Cummins Launches Industry-First Hydrogen Internal Combustion Engine Turbochargers for On-Highway Applications
Cummins Global power and technology leader Cummins Inc. (NYSE: CMI), is pleased to announce the launch of its new turbocharger designed specifically for hydrogen internal combustion engines (H2 ICE). This advancement in turbocharging technology marks a significant milestone for heavy-duty commercial on-highway applications in Europe. Cummins Components and Software (CCS), part of Cummins' Components business segment, has secured a contract to supply H2 ICE turbochargers to a major European OEM, showcasing its leadership in hydrogen innovation. The H2 ICE turbocharger meets the industry's growing demand for efficient and sustainable solutions, supporting the transition to low-emission transportation. It is specifically designed to power the first hydrogen internal combustion engine for heavy-duty on-highway applications in the European market. Pioneering innovation to support global decarbonization efforts The integration of the H2ICE turbocharger into hydrogen-powered heavy-duty vehicles reinforces Cummins' commitment to delivering sustainable and cost-effective solutions for decarbonizing transportation. H2 ICE engine technology has been classified as zero-emission by the European Union (EU) and represents a promising bridge solution for reducing emissions. H2ICE engine platforms also comply with the upcoming Euro VII emission standards, demonstrating the potential of hydrogen as a viable alternative in the journey toward global decarbonization. Innovation leadership in turbocharging technologies The Cummins H2 ICE variable geometry turbocharger has been meticulously engineered to meet the unique requirements of hydrogen engines. With bespoke aerodynamics and advanced prognostics, the turbocharger optimizes performance under the challenging conditions presented by hydrogen combustion. The product is a cornerstone of Cummins' Destination Zero strategy, which aims to achieve decarbonization by working with partners across industries to develop cutting-edge, sustainable technologies. Key Features of the CCS H2 ICE Turbocharger: Challenges and Successes During the development of the turbocharger, Cummins overcame significant challenges posed by the use of hydrogen as a fuel. These included adapting aerodynamics to address varying lambda requirements, managing the increased water production resulting from hydrogen combustion, and mitigating the metallurgical impacts of hydrogen use. Despite these hurdles, Cummins has successfully delivered a reliable and high-performance turbocharger for hydrogen powered heavy-duty on-highway truck engines. To know more about Cummins' turbocharging technology and innovations, please visit Turbochargers | Cummins Inc. About Cummins Inc. Cummins Inc., a global power solutions leader, comprises five business segments - Engine, Components, Distribution, Power Systems and Accelera by Cummins - supported by its global manufacturing and extensive service and support network, skilled workforce and vast technological expertise. Cummins is committed to its Destination Zero strategy, which is grounded in the company's commitment to sustainability and helping its customers successfully navigate the energy transition with its broad portfolio of products. The products range from advanced diesel, natural gas, electric and hybrid powertrains and powertrain-related components including aftertreatment, turbochargers, fuel systems, valvetrain technologies, controls systems, air handling systems, automated transmissions, axles, drivelines, brakes, suspension systems, electric power generation systems, electrified power systems with innovative components and subsystems, including battery, fuel cell and electric power technologies and hydrogen production technologies. Headquartered in Columbus, Indiana (U.S.), since its founding in 1919, Cummins employs approximately 69,600 people committed to powering a more prosperous world through three global corporate responsibility priorities critical to healthy communities: education, environment and equality of opportunity. Cummins serves its customers online, through a network of company-owned and independent distributor locations, and through thousands of dealer locations worldwide and earned about $3.9 billion on sales of $34.1 billion in 2024. See how Cummins is leading your world toward a future of smarter, cleaner power at Media Contact Melinda KoskiExternal Communications Director317.476.3293 Email
Associated Press
32 minutes ago
- Associated Press
JCR Pharmaceuticals Announces the Achievement of Enrollment in the JR-141 Global Phase III Clinical Trial
HYOGO, Japan--(BUSINESS WIRE)--Jul 2, 2025-- JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR) announced that it achieved the enrollment of the target number of participants in the global Phase III clinical trial of JR-141 (INN: pabinafusp alfa), which is in development for the treatment of mucopolysaccharidosis type II (MPS II, also known as Hunter syndrome). The Phase III clinical trial is ongoing in the United States, Latin America, and Europe. ( JR-141-GS31 ) JR-141 is a recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase, the enzyme that is missing or malfunctioning in people with Hunter syndrome. JR-141 was developed using J-Brain Cargo ®, JCR's proprietary blood-brain barrier (BBB)-penetrating technology, which is designed to deliver biotherapeutics across the BBB into the central nervous system (CNS) to address the neurological symptoms of Hunter syndrome. 'This achievement is a milestone in the JR-141 clinical development program, as the Hunter syndrome community needs a therapy that treats the cognitive symptoms of this devastating and life-threatening disease for which there are inadequate treatment options available,' said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. 'We are making good progress in this global Phase III clinical trial, and we look forward to sharing the clinical data as they are available. Thank you to all the participants who are part of this clinical trial.' In March 2021, the Ministry of Health, Labour and Welfare (MHLW) in Japan approved JR-141 (also known by the brand name IZCARGO ® ) for a lysosomal storage disorder. JR-141 is the first-ever approved ERT in the world that penetrates the BBB. About JR-141 JR-141 (INN: pabinafusp alfa) is a recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase, the enzyme that is missing or malfunctioning in subjects with Hunter syndrome. It incorporates J-Brain Cargo ®, JCR's proprietary blood-brain barrier (BBB)-penetrating technology, to cross the BBB through transferrin receptor-mediated transcytosis, and its uptake into cells is mediated through the mannose-6-phosphate receptor. This novel mechanism of action is expected to make JR-141 effective against the central nervous system (CNS) symptoms of Hunter syndrome. In non-clinical trials, JCR has confirmed both high-affinity binding of pabinafusp alfa to transferrin receptors and passage across the BBB into neuronal cells. In addition, JCR has confirmed enzyme uptake in various brain tissues. The company has also confirmed a reduction of substrate accumulation in the CNS and peripheral organs in an animal model of Hunter syndrome. 1,2 In several clinical trials of pabinafusp alfa, JCR obtained evidence of reducing heparan sulfate concentrations in the cerebrospinal fluid, a biomarker for assessing effectiveness against CNS symptoms; these results were consistent with those obtained in pre-clinical studies. 3 Clinical studies have also demonstrated the positive effects of pabinafusp alfa on CNS symptoms. 4,5,6 About Mucopolysaccharidosis Type II (Hunter Syndrome) Mucopolysaccharidosis type II (MPS II, or Hunter syndrome) is an X-linked recessive lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase, an enzyme that breaks down complex carbohydrates called glycosaminoglycans (GAGs, also known as mucopolysaccharides) in the body. Hunter syndrome, which affects an estimated 2,000-3,000 individuals worldwide (according to JCR research), gives rise to a wide range of somatic and neurological symptoms. The current standard of care for Hunter syndrome is enzyme replacement therapy. Central nervous system symptoms related to MPS II have been unmet medical needs so far. About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit JCR's global website: Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as 'believe,' 'estimate,' 'anticipate,' 'intend,' 'plan,' 'will,' 'would,' 'target' and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions. This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future. 2: Morimoto, et al. Clearance of heparin sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice. Mol. Ther. 2021; 29(5): 1853-1861. 3: Okuyama, et al. Iduronate-2-sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial. Mol Ther. 2020; 27(2): 456-464. 4: Okuyama, et al. A Phase 2/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II. Mol Ther. 2021; 29(2): 671-679. 5: Giugliani, et al. Iduronate-2-sulfatase fused with anti-human transferrin receptor antibody, pabinafusp alfa, for treatment of neuronopathic and non-neuronopathic mucopolysaccharidosis II: Report of a phase 2 trial in Brazil. Mol Ther. 2021; 29(7): 2378-2386. 6: Giugliani, et al. Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II; an Integrated Analysis of Preclinical and Clinical Data. Int. J. Mol. Sci. 2021, Volume 22, Issue 20, 10938. View source version on CONTACT: Investors & Media: JCR Pharmaceuticals Co., Ltd. Corporate Communications [email protected] KEYWORD: UNITED STATES JAPAN NORTH AMERICA ASIA PACIFIC INDUSTRY KEYWORD: RESEARCH NEUROLOGY CLINICAL TRIALS BIOTECHNOLOGY HEALTH PHARMACEUTICAL GENERAL HEALTH OTHER SCIENCE SCIENCE SOURCE: JCR Pharmaceuticals Co., Ltd. Copyright Business Wire 2025. PUB: 07/02/2025 11:12 AM/DISC: 07/02/2025 11:12 AM
Associated Press
32 minutes ago
- Associated Press
$5.91 Billion Market is Scaling Through Platform Expansion, OEM Trade-In, and Circular Retail Enablements - Forecast to 2029
DUBLIN--(BUSINESS WIRE)--Jul 2, 2025-- The 'India Recommerce Market Intelligence Databook - 60+ KPIs, Market Size, Share & Forecast by Channel, Category & Consumer Segment - Q2 2025 Update' report has been added to offering. The recommerce market in India is on a promising trajectory, projected to grow by 11.7% annually, reaching USD 5.91 billion by 2025. From 2020 to 2024, the market witnessed a significant CAGR of 14.6%, and it is anticipated to maintain a positive growth rate of 9.8% from 2025 to 2029, ultimately expanding to USD 8.61 billion by 2029. This report provides a detailed data-centric analysis of the recommerce market in India, covering market opportunities and risks across consumer segments (peer-to-peer and business-led resale); product categories; sales channels; and resale formats. With over 60+ KPIs at the country level, this report provides a comprehensive understanding of recommerce market dynamics. It offers a comprehensive analysis of market dynamics in the recommerce market, segmented by recommerce channels (C2C, B2C, trade-in programs), sales models (resale, rental, refurbishment), platform types (generalist and vertical-specific), digital engagement (app, website, social media), and retail categories (electronics, apparel, home goods, and more). In addition, it provides a snapshot of consumer behaviour, device usage, payment preferences, and city-level penetration across Tier 1 to Tier 3 cities. Recommerce in India Is Scaling Through Platform Expansion, OEM Trade-In, and Circular Retail Enablement India's recommerce sector is undergoing rapid expansion driven by mobile-led consumption, digital resale platforms, and retailer-OEM trade-in models. Consumer electronics remain the largest recommerce category, with fashion and furniture following. The segment is scaling through affordability, logistics reach, and emerging sustainability disclosures. Electronics Recommerce Is Expanding Through OEM Trade-In and Warranty-Backed Resale Fashion Recommerce Is Scaling via Platform Partnerships and Social Commerce Retailers Are Embedding Recommerce into Storefront Take-Back and Reverse Logistics Platform Recommerce Is Becoming Verticalized and Financially Enabled ESG Mandates and E-Waste Policies Are Enabling Circular Economy Channels Company Coverage: Report Scope India Recommerce Market Size and Growth Dynamics India Recommerce Market Size and Forecast by Sector India Recommerce Market Size and Forecast by Retail Category India Recommerce by Channel India Recommerce by Sales Model India Recommerce by Digital Engagement Channel India Recommerce by Platform Type India Recommerce by Device and OS India Recommerce by City Tier India Recommerce by Payment Instrument India Recommerce Market Share Analysis India Recommerce by Consumer Demographics For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDIA ASIA PACIFIC INDUSTRY KEYWORD: FASHION SUPPLY CHAIN MANAGEMENT ONLINE RETAIL RETAIL CONSUMER ELECTRONICS TECHNOLOGY SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 07/02/2025 11:20 AM/DISC: 07/02/2025 11:20 AM
